Literature DB >> 10780782

The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders.

C Cardoso1, C Mignon, G Hetet, B Grandchamps, M Fontes, L Colleaux.   

Abstract

The EZH2 gene is a homolog of the Drosophila Polycomb group (PcG) gene enhancer of zest, a crucial regulator of homeotic gene expression. Several lines of evidence suggest a critical role for the EZH2 protein during normal and perturbed development of the haematopoietic and central nervous systems. Indeed, the EZH2 protein has been shown to associate with the Vav proto-oncoprotein and with the XNP protein, the product of a mental retardation gene. The EZH2 gene was previously reported to be located on chromosome 21q22 and was proposed as a candidate gene for some characteristics of the Down syndrome phenotype. We report here the genomic structure and fine mapping of the EZH2 gene. We demonstrate that the functional gene actually maps to chromosome 7q35 and that the sequence previously isolated from a chromosome 21 cosmid corresponds to a pseudogene. Finally, the nature of the EZH2 protein and its mapping to the critical region for malignant myeloid disorders lead us to propose the EZH2 gene is involved in the pathogenesis of 7q35-q36 aberrations in myeloid leukaemia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780782     DOI: 10.1038/sj.ejhg.5200439

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  33 in total

Review 1.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  MicroRNA-1297 regulates hepatocellular carcinoma cell proliferation and apoptosis by targeting EZH2.

Authors:  Fenghua Liu; Yukai He; Ronghua Shu; Sikui Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma.

Authors:  Tian-Yu Fan; Hai Wang; Peng Xiang; Ya-Wei Liu; He-Zhen Li; Bing-Xi Lei; Meng Yu; Song-Tao Qi
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population.

Authors:  Jian Wang; Zhen-Bin Ma; Kun Li; Guang-Hong Guo
Journal:  Med Oncol       Date:  2014-02-02       Impact factor: 3.064

Review 5.  EZH2: not EZHY (easy) to deal.

Authors:  Gauri Deb; Anup Kumar Singh; Sanjay Gupta
Journal:  Mol Cancer Res       Date:  2014-02-13       Impact factor: 5.852

6.  Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Authors:  Andrei V Ougolkov; Vladimir N Bilim; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  Remarkable compartmentalization of transposable elements and pseudogenes in the heterochromatin of the Tetraodon nigroviridis genome.

Authors:  Corinne Dasilva; Hajer Hadji; Catherine Ozouf-Costaz; Sophie Nicaud; Olivier Jaillon; Jean Weissenbach; Hugues Roest Crollius
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

8.  EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.

Authors:  Adrian P Bracken; Diego Pasini; Maria Capra; Elena Prosperini; Elena Colli; Kristian Helin
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

9.  LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.

Authors:  Neil Beeharry; Sean Landrette; Sophia Gayle; Marylens Hernandez; Jeff E Grotzke; Peter R Young; Paul Beckett; Xuan Zhang; Bing Z Carter; Michael Andreeff; Stephanie Halene; Tian Xu; Jonathan Rothberg; Henri Lichenstein
Journal:  Blood Adv       Date:  2019-11-26

10.  Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines.

Authors:  An De Weer; Bruce Poppe; Sarah Vergult; Pieter Van Vlierberghe; Marjan Petrick; Robrecht De Bock; Yves Benoit; Lucien Noens; Anne De Paepe; Nadine Van Roy; Björn Menten; Frank Speleman
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.